Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States

BACKGROUND: Chronic lymphocytic leukemia (CLL) is a significant health and economic burden in the United States. Treatments include chemoimmunotherapy, such as obinutuzumab (G) plus chlorambucil (Clb) or bendamustine plus rituximab (BR), and chemotherapy-free regimens incorporating oral targeted the...

Descripción completa

Detalles Bibliográficos
Autores principales: Chatterjee, Anuja, Shapouri, Sheila, Manzoor, Beenish S, Ravelo, Arliene, Sail, Kavita, Qendri, Venetia, van de Wetering, Gijs, Davids, Matthew S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391182/
https://www.ncbi.nlm.nih.gov/pubmed/34714110
http://dx.doi.org/10.18553/jmcp.2021.27.11.1532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391182/
https://www.ncbi.nlm.nih.gov/pubmed/34714110
http://dx.doi.org/10.18553/jmcp.2021.27.11.1532

Ejemplares similares